Source:http://linkedlifedata.com/resource/pubmed/id/19321044
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2009-3-26
|
pubmed:abstractText |
Nasal obstruction is a leading symptom in patients with allergic rhinitis and depends on inflammation characterized by Th2 polarization. Thus, IFN-gamma is typically deficient in allergic patients. It has been previously reported that ebastine is able to reduce Th2-dependent cytokines. The aim of this study is to preliminarily evaluate IFN-gamma production by peripheral blood mononuclear cells (PBMNC) and clinical changes after a treatment with lyophilized ebastine in patients with persistent allergic rhinitis (PER). Ten patients with PER were evaluated, 7 males and 3 females (mean age 32.4 +/- 6.2 years), all of whom received lyophilized ebastine (20 mg/daily) for 3 weeks. Total nasal symptom score (TSS), subjective evaluation score by visual analogue scale (VAS), and rhinomanometry were evaluated in all subjects before and after treatment. IFN-gamma production by peripheral blood mononuclear cells (PBMNC) was evaluated using different stimuli, in un-treated and ebastine-treated allergic patients by ELISPOT. Ebastine treatment induced significant increase of IFN-gamma production stimulated by grasses (p<0.0001) and Dermatophagoides farinae (p=0.0015). This effect was significantly related with TSS and VAS improvement after treatment (p=0.0038 and 0.004 respectively). In conclusion, this preliminary study demonstrates the effectiveness of ebastine treatment in increasing IFN-gamma production. The clinical relevance of this study is that the clinical improvement is related to the immunologic activity.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Butyrophenones,
http://linkedlifedata.com/resource/pubmed/chemical/Histamine H1 Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Piperidines,
http://linkedlifedata.com/resource/pubmed/chemical/ebastine
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0393-974X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
31-6
|
pubmed:meshHeading |
pubmed-meshheading:19321044-Adult,
pubmed-meshheading:19321044-Butyrophenones,
pubmed-meshheading:19321044-Female,
pubmed-meshheading:19321044-Histamine H1 Antagonists,
pubmed-meshheading:19321044-Humans,
pubmed-meshheading:19321044-Interferon-gamma,
pubmed-meshheading:19321044-Male,
pubmed-meshheading:19321044-Piperidines,
pubmed-meshheading:19321044-Rhinitis, Allergic, Perennial,
pubmed-meshheading:19321044-Rhinomanometry
|
pubmed:articleTitle |
Ebastine increases IFN-gamma production in patients with persistent allergic rhinitis.
|
pubmed:affiliation |
DIMI-CEBR, University of Genoa, Genoa, Italy.
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|